Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cortexyme, Inc. stock logo
CRTX
Cortexyme
$1.40
+1.4%
$1.50
$1.78
$40.66
$42.21M1.4620,672 shs265,370 shs
HealthStream, Inc. stock logo
HSTM
HealthStream
$32.01
-0.1%
$32.59
$23.92
$34.24
$974.19M0.37121,809 shs107,816 shs
Veradigm Inc. stock logo
MDRX
Veradigm
$4.19
-1.4%
$5.88
$4.00
$11.80
$451.01M0.56502,752 shs340,433 shs
Omnicell, Inc. stock logo
OMCL
Omnicell
$34.47
-1.9%
$39.47
$25.12
$55.75
$1.61B0.85498,280 shs357,728 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cortexyme, Inc. stock logo
CRTX
Cortexyme
0.00%-4.17%-4.83%-21.59%+15.00%
HealthStream, Inc. stock logo
HSTM
HealthStream
+1.52%+3.19%-2.59%+1.30%+21.19%
Veradigm Inc. stock logo
MDRX
Veradigm
-5.56%-15.34%-16.67%-54.30%-46.54%
Omnicell, Inc. stock logo
OMCL
Omnicell
+3.54%+5.78%-11.53%-18.66%+25.81%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cortexyme, Inc. stock logo
CRTX
Cortexyme
N/AN/AN/AN/AN/AN/AN/AN/A
HealthStream, Inc. stock logo
HSTM
HealthStream
3.9695 of 5 stars
1.44.01.74.82.63.30.6
Veradigm Inc. stock logo
MDRX
Veradigm
2.9347 of 5 stars
3.30.00.04.12.10.00.0
Omnicell, Inc. stock logo
OMCL
Omnicell
2.2588 of 5 stars
3.22.00.00.02.01.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cortexyme, Inc. stock logo
CRTX
Cortexyme
0.00
N/AN/AN/A
HealthStream, Inc. stock logo
HSTM
HealthStream
2.80
Moderate Buy$32.00-0.03% Downside
Veradigm Inc. stock logo
MDRX
Veradigm
2.50
Moderate Buy$14.00234.13% Upside
Omnicell, Inc. stock logo
OMCL
Omnicell
2.33
Hold$51.0047.95% Upside

Current Analyst Ratings Breakdown

Latest HSTM, OMCL, MDRX, and CRTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/20/2025
Omnicell, Inc. stock logo
OMCL
Omnicell
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$44.00 ➝ $36.00
2/26/2025
HealthStream, Inc. stock logo
HSTM
HealthStream
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$29.00 ➝ $30.00
2/25/2025
HealthStream, Inc. stock logo
HSTM
HealthStream
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
2/6/2025
HealthStream, Inc. stock logo
HSTM
HealthStream
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform
2/4/2025
Omnicell, Inc. stock logo
OMCL
Omnicell
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$62.00 ➝ $62.00
1/31/2025
Veradigm Inc. stock logo
MDRX
Veradigm
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$7.00 ➝ $13.00
1/13/2025
Omnicell, Inc. stock logo
OMCL
Omnicell
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$49.00 ➝ $40.00
1/6/2025
Omnicell, Inc. stock logo
OMCL
Omnicell
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$54.00 ➝ $46.00
(Data available from 3/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cortexyme, Inc. stock logo
CRTX
Cortexyme
N/AN/AN/AN/A$3.97 per shareN/A
HealthStream, Inc. stock logo
HSTM
HealthStream
$291.65M3.34$2.13 per share15.00$11.25 per share2.85
Veradigm Inc. stock logo
MDRX
Veradigm
$1.53B0.29N/AN/AN/A
Omnicell, Inc. stock logo
OMCL
Omnicell
$1.11B1.45$2.66 per share12.95$26.84 per share1.28
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cortexyme, Inc. stock logo
CRTX
Cortexyme
-$89.94M-$2.97N/AN/AN/AN/A-70.96%-63.53%N/A
HealthStream, Inc. stock logo
HSTM
HealthStream
$15.21M$0.6649.2550.024.376.84%5.67%3.91%4/28/2025 (Estimated)
Veradigm Inc. stock logo
MDRX
Veradigm
N/AN/A0.00N/AN/AN/AN/AN/A
Omnicell, Inc. stock logo
OMCL
Omnicell
$12.53M$0.27127.6727.807.531.13%3.82%2.07%5/1/2025 (Estimated)

Latest HSTM, OMCL, MDRX, and CRTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/24/2025Q4 2024
HealthStream, Inc. stock logo
HSTM
HealthStream
$0.13$0.16+$0.03$0.16$73.55 million$74.24 million
2/6/2025Q4 2024
Omnicell, Inc. stock logo
OMCL
Omnicell
$0.57$0.45-$0.12$0.34$297.88 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cortexyme, Inc. stock logo
CRTX
Cortexyme
N/AN/AN/AN/AN/A
HealthStream, Inc. stock logo
HSTM
HealthStream
$0.120.37%N/A18.18%N/A
Veradigm Inc. stock logo
MDRX
Veradigm
N/AN/AN/AN/AN/A
Omnicell, Inc. stock logo
OMCL
Omnicell
N/AN/AN/AN/AN/A

Latest HSTM, OMCL, MDRX, and CRTX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/24/2025
HealthStream, Inc. stock logo
HSTM
HealthStream
quarterly$0.03100.4%3/10/20253/10/20253/21/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cortexyme, Inc. stock logo
CRTX
Cortexyme
N/A
9.92
9.92
HealthStream, Inc. stock logo
HSTM
HealthStream
N/A
1.32
1.32
Veradigm Inc. stock logo
MDRX
Veradigm
N/AN/AN/A
Omnicell, Inc. stock logo
OMCL
Omnicell
0.13
1.37
1.22

Institutional Ownership

CompanyInstitutional Ownership
Cortexyme, Inc. stock logo
CRTX
Cortexyme
63.18%
HealthStream, Inc. stock logo
HSTM
HealthStream
69.58%
Veradigm Inc. stock logo
MDRX
Veradigm
N/A
Omnicell, Inc. stock logo
OMCL
Omnicell
97.70%

Insider Ownership

CompanyInsider Ownership
Cortexyme, Inc. stock logo
CRTX
Cortexyme
27.90%
HealthStream, Inc. stock logo
HSTM
HealthStream
20.60%
Veradigm Inc. stock logo
MDRX
Veradigm
2.29%
Omnicell, Inc. stock logo
OMCL
Omnicell
2.64%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cortexyme, Inc. stock logo
CRTX
Cortexyme
5530.15 million21.74 millionNot Optionable
HealthStream, Inc. stock logo
HSTM
HealthStream
1,14030.43 million24.15 millionOptionable
Veradigm Inc. stock logo
MDRX
Veradigm
8,000107.64 million105.18 millionNo Data
Omnicell, Inc. stock logo
OMCL
Omnicell
3,65046.76 million45.09 millionOptionable

Recent News About These Companies

Omnicell price target lowered to $36 from $44 at JPMorgan
Omnicell, Inc. (OMCL) Stock Forecasts
Omnicell price target lowered to $38 from $46 at BofA
Omnicell reiterates Q1, FY25 guidance
Omnicell Finance Chief to Step Down By September
Omnicell Announces Chief Financial Officer Transition
Omnicell CFO Nchacha Etta to step down
Omnicell's (NASDAQ:OMCL) Earnings Seem To Be Promising
Omnicell CFO Nchacha Etta Announces Departure

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cortexyme stock logo

Cortexyme NASDAQ:CRTX

$1.40 +0.02 (+1.45%)
As of 03/24/2025

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

HealthStream stock logo

HealthStream NASDAQ:HSTM

$32.01 -0.02 (-0.06%)
As of 04:00 PM Eastern

HealthStream, Inc. provides Software-as-a-Service (SaaS) based applications for healthcare organizations in the United States. The company's solutions help healthcare organizations in meeting their ongoing clinical development, talent management, training, education, assessment, competency management, safety and compliance, and scheduling, as well as provider credentialing, privileging, and enrollment needs. It offers hStream, a technology platform that powers a range of healthcare workforce solutions. The company provides its solutions to customers across a range of entities within the healthcare industry, including private, not-for-profit, and government entities, as well as pharmaceutical and medical device companies through its direct sales teams. The company was incorporated in 1990 and is headquartered in Nashville, Tennessee.

Veradigm stock logo

Veradigm NASDAQ:MDRX

$4.19 -0.06 (-1.41%)
As of 03:35 PM Eastern

Veradigm Inc., a healthcare technology company, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions. The company operates through two segments, Hospitals and Large Physician Practices, and Veradigm. The Hospitals and Large Physician Practices segment provides integrated clinical and financial management solutions, which primarily include EHR-related software; and related installation, support and maintenance, outsourcing, private cloud hosting, and revenue cycle management services. The Veradigm segment offers payer and life sciences solutions, which are primarily targeted at payers, life sciences companies, and other healthcare stakeholders; and software applications for patient engagement and EHR software to single-specialty, and small and mid-sized physician practices, including related clinical, financial, administrative, and operational solutions. Its solutions enable clients to transition, analyze, and coordinate care, and enhance the healthcare delivery across the care community. The company serves physicians, hospitals, governments and militaries, health systems, health plans, life-sciences companies, retail clinics, surgery centers, retail pharmacies, pharmacy benefit managers, insurance companies, employer wellness clinics, consumers, lab companies, urgent care facilities, and venture capital firms, as well as post-acute organizations, such as home health and hospice agencies. The company was formerly known as Allscripts Healthcare Solutions, Inc. and changed its name to Veradigm Inc. in January 2023. Veradigm Inc. was founded in 1986 and is headquartered in Chicago, Illinois.

Omnicell stock logo

Omnicell NASDAQ:OMCL

$34.47 -0.67 (-1.91%)
Closing price 04:00 PM Eastern
Extended Trading
$34.86 +0.39 (+1.14%)
As of 05:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.